Vanguard Global Advisers
MIRA icon

Vanguard Global Advisers’s MIRA Pharmaceuticals MIRA Stock Holding History

Vanguard Global Advisers’s Portfolio MIRA Stock Details MIRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,306
Closed -$26K – 3705
2026
Q1 		$26K Buy
+24,306
New +$30.5K ﹤0.01% 3242

Other funds holding MIRA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CSI
Cross Staff Investments Pittsford, New York $178M AUM 21.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
FAB
First American Bank Dundee, Illinois $1.79B AUM 30.35% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's MIRA Position: Q2 2026 in Review

Vanguard Global Advisers sold out of MIRA Pharmaceuticals (MIRA) in Q2 2026, closing a stake of 24,306 shares — an estimated $26K sold.

Vanguard Global Advisers first reported a position in MIRA in Q1 2026 and held it in 1 quarter. The position peaked at $26K in Q1 2026. 26 funds tracked by Wall St. Rank hold MIRA as of Q2 2026.

  • Vanguard Global Advisers reported no remaining MIRA Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 24,306 MIRA Pharmaceuticals shares in Q2 2026, an estimated $26K.
  • Vanguard Global Advisers first reported a position in MIRA Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's MIRA Pharmaceuticals position peaked at $26K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held MIRA Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.